TransCode Therapeutics (RNAZ) Competitors $0.40 -0.01 (-2.93%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$0.40 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAZ vs. CLNN, TPST, TENX, PASG, CARA, LIAN, CGTX, FNCH, OVID, and LGVNShould you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Clene (CLNN), Tempest Therapeutics (TPST), Tenax Therapeutics (TENX), Passage Bio (PASG), Cara Therapeutics (CARA), LianBio (LIAN), Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Ovid Therapeutics (OVID), and Longeveron (LGVN). These companies are all part of the "pharmaceutical products" industry. TransCode Therapeutics vs. Clene Tempest Therapeutics Tenax Therapeutics Passage Bio Cara Therapeutics LianBio Cognition Therapeutics Finch Therapeutics Group Ovid Therapeutics Longeveron Clene (NASDAQ:CLNN) and TransCode Therapeutics (NASDAQ:RNAZ) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability. Which has more risk & volatility, CLNN or RNAZ? Clene has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500. Comparatively, TransCode Therapeutics has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500. Do analysts prefer CLNN or RNAZ? Clene currently has a consensus target price of $55.25, indicating a potential upside of 1,699.67%. TransCode Therapeutics has a consensus target price of $20.00, indicating a potential upside of 4,925.13%. Given TransCode Therapeutics' higher probable upside, analysts plainly believe TransCode Therapeutics is more favorable than Clene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20TransCode Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CLNN or RNAZ more profitable? TransCode Therapeutics has a net margin of 0.00% compared to Clene's net margin of -8,556.77%. TransCode Therapeutics' return on equity of -649.03% beat Clene's return on equity.Company Net Margins Return on Equity Return on Assets Clene-8,556.77% -1,106.30% -85.11% TransCode Therapeutics N/A -649.03%-281.34% Does the MarketBeat Community prefer CLNN or RNAZ? Clene received 66 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 93.75% of users gave TransCode Therapeutics an outperform vote while only 81.00% of users gave Clene an outperform vote. CompanyUnderperformOutperformCleneOutperform Votes8181.00% Underperform Votes1919.00%TransCode TherapeuticsOutperform Votes1593.75% Underperform Votes16.25% Which has preferable earnings and valuation, CLNN or RNAZ? TransCode Therapeutics has lower revenue, but higher earnings than Clene. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClene$342K77.16-$49.50M-$5.75-0.53TransCode TherapeuticsN/AN/A-$18.55MN/AN/A Do insiders and institutionals hold more shares of CLNN or RNAZ? 23.3% of Clene shares are owned by institutional investors. 25.1% of Clene shares are owned by company insiders. Comparatively, 2.8% of TransCode Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to CLNN or RNAZ? In the previous week, Clene had 2 more articles in the media than TransCode Therapeutics. MarketBeat recorded 4 mentions for Clene and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 0.43 beat Clene's score of 0.12 indicating that TransCode Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Clene Neutral TransCode Therapeutics Neutral SummaryClene beats TransCode Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAZ vs. The Competition Export to ExcelMetricTransCode TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.21M$6.33B$5.33B$7.57BDividend YieldN/A3.24%5.11%4.32%P/E RatioN/A6.7921.7217.82Price / SalesN/A225.96376.8894.61Price / CashN/A65.6738.1534.64Price / Book0.005.866.474.00Net Income-$18.55M$141.86M$3.20B$247.23M7 Day Performance4.33%4.50%2.86%1.45%1 Month Performance-48.83%-12.65%-8.55%-6.24%1 Year Performance-99.93%-11.06%10.58%0.60% TransCode Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAZTransCode Therapeutics2.2149 of 5 stars$0.40-2.9%$20.00+4,925.1%-99.9%$5.21MN/A0.009Short Interest ↑Gap DownCLNNClene2.8861 of 5 stars$2.69-0.2%$55.25+1,957.7%-53.7%$23.08M$342,000.00-0.51100Short Interest ↑TPSTTempest Therapeutics2.2868 of 5 stars$0.51-17.6%$9.33+1,745.3%-82.8%$23.01MN/A-0.3320Short Interest ↓TENXTenax Therapeutics2.0583 of 5 stars$5.75-0.9%$18.00+213.0%+54.0%$22.83MN/A-1.089Analyst ForecastPASGPassage Bio2.3759 of 5 stars$0.35+3.0%$7.50+2,042.2%-70.0%$21.76MN/A-0.30130CARACara Therapeutics3.8999 of 5 stars$4.75-1.0%$27.84+486.1%-37.6%$21.73M$7.14M-0.2380Analyst ForecastStock SplitNews CoverageGap DownLIANLianBioN/A$0.20+0.1%N/A-33.4%$21.61MN/A-0.25110CGTXCognition Therapeutics3.1864 of 5 stars$0.35-2.0%$7.13+1,953.3%-79.9%$21.51MN/A-0.3620Gap DownFNCHFinch Therapeutics GroupN/A$13.16-2.5%N/A+492.4%$21.14M$110,000.00-1.49190OVIDOvid Therapeutics4.4257 of 5 stars$0.29+2.2%$3.03+953.6%-91.1%$20.46M$566,000.00-0.6160Gap DownLGVNLongeveron2.9999 of 5 stars$1.35-3.6%$8.67+542.0%-50.2%$20.15M$2.39M-0.2120Positive News Remove Ads Related Companies and Tools Related Companies Clene Competitors Tempest Therapeutics Competitors Tenax Therapeutics Competitors Passage Bio Competitors Cara Therapeutics Competitors LianBio Competitors Cognition Therapeutics Competitors Finch Therapeutics Group Competitors Ovid Therapeutics Competitors Longeveron Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAZ) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RNAZ Stock Free RNAZ Stock Alerts